AbbVie Inc. and Merz Holding Gmbh & Co. affiliates received final approval for a $54.4 million settlement of a lawsuit that claimed the pharmaceutical companies conspired to block generic competition for the Alzheimer’s drug Namenda.
The settlement, approved by Judge Colleen McMahon in the US District Court for the Southern District of New York on Thursday, comes after nearly eight years of litigation.
McMahon gave preliminary approval for the settlement in November 2022.
Sergeants Benevolent Association Health and Welfare Fund (SBA) in 2015 filed class action claims against Forest Laboratories, an AbbVie unit, and a Merz subsidiary, as well as ...